Open Access. Powered by Scholars. Published by Universities.®
Articles 1 - 2 of 2
Full-Text Articles in Clinical Trials
Reply To: S. N. Katkuri Et Al. And H. Liu Et Al. On Early And Sustained Improvements In Sense Of Smell With Tezepelumab Treatment In Patients With Chronic Rhinosinusitis With Nasal Polyps (Waypoint), Joaquim Mullol, Joseph K. Han, Tanya M. Laidlaw, Claire Hopkins, Anju T. Peters, Oliver Pfaar, Martin Desrosiers, Stella E. Lee, Andrew P. Lane, Claudia Chen, Yun Chon, Sandhia S. Ponnarambil, Andrew Foster, Andrew W. Lindsley, Christopher S. Ambrose
Reply To: S. N. Katkuri Et Al. And H. Liu Et Al. On Early And Sustained Improvements In Sense Of Smell With Tezepelumab Treatment In Patients With Chronic Rhinosinusitis With Nasal Polyps (Waypoint), Joaquim Mullol, Joseph K. Han, Tanya M. Laidlaw, Claire Hopkins, Anju T. Peters, Oliver Pfaar, Martin Desrosiers, Stella E. Lee, Andrew P. Lane, Claudia Chen, Yun Chon, Sandhia S. Ponnarambil, Andrew Foster, Andrew W. Lindsley, Christopher S. Ambrose
Department of Otolaryngology (ENT) Faculty Publications
[Introduction] We thank Dr. S. N. Katkuri, Dr. H. Liu, and their coauthors [1, 2] for their interest in our recent publication describing the improvements in loss of smell symptoms with tezepelumab versus placebo in patients with uncontrolled chronic rhinosinusitis with nasal polyps (CRSwNP) in the WAYPOINT trial (NCT04851964) [3]. We are grateful for the authors' feedback on the clinical significance of the data presented and their appreciation of the consistency observed across a range of baseline clinical characteristic and demographic subgroups.
Lessons Learned From Clinical Trials Of Thymic Stromal Lymphopoietin (Tslp) Inhibition, Jonathan Corren, Larry Borish, Christopher Brightling, Joseph K. Han, Emma Guttman-Yassky, Steven Ziegler, Jean Publicover, Jyotsna Gulati, Nestor Molfino, Christopher S. Ambrose, Jean-Pierre Llanos, Lang Chen, Jane R. Parnes, Joseph Spahn, Andrew Lindsley
Lessons Learned From Clinical Trials Of Thymic Stromal Lymphopoietin (Tslp) Inhibition, Jonathan Corren, Larry Borish, Christopher Brightling, Joseph K. Han, Emma Guttman-Yassky, Steven Ziegler, Jean Publicover, Jyotsna Gulati, Nestor Molfino, Christopher S. Ambrose, Jean-Pierre Llanos, Lang Chen, Jane R. Parnes, Joseph Spahn, Andrew Lindsley
Department of Otolaryngology (ENT) Faculty Publications
Type 2 (T2) immune–mediated epithelial-driven diseases are characterized by dysregulated immune responses at epithelial barrier surfaces. A key mediator of these diseases is thymic stromal lymphopoietin (TSLP), an epithelial cytokine that acts as a regulator of both T2 and non-T2 inflammation. TSLP activates dendritic cells and other immune cells, promoting the release of proinflammatory cytokines, including IL-4, IL-5, and IL-13. Given its central role in initiating and amplifying T2 inflammation, TSLP has emerged as a promising therapeutic target in multiple epithelial-driven inflammatory diseases. Tezepelumab is a human monoclonal antibody that selectively blocks TSLP from interacting with its receptor complex, thereby …